ARQ 501 (Fig. 1) is an investigational anticancer agent that consists of a fully synthetic small molecule (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione, -lapachone, molecular mass 242 Da) in a stable HPCD formulation suitable for intravenous administration. In preclinical studies in vitro (Docampo et al., 1979; SchaffnerSabba et al., 1984;Chau et al., 1998;Li et al., 2000) and in vivo (Li et al., 1999;Ough et al., 2005), ARQ 501 showed activity against a variety of cancers. In a phase Ib clinical study, ARQ 501 showed promising anticancer activity against pancreatic cancer when administered in combination with gemcitabine. ARQ-501 is currently in several phase II cancer trials.Most pharmaceutical products (ϳ80%) that undergo biotransformation are cleared by the phase I cytochrome P450 enzymes (Coughtrie and Fisher, 2003). However, it is widely known that a second class of enzymes, the phase II enzymes, also plays a significant role in drug metabolism. Among the most common phase II enzymes are the UDPglucuronosyltransferases (UGTs), the sulfotransferases (SULTs), and the glutathione transferases (GSTs). Phase II metabolites are easily identified by mass spectrometry, as these biotransformation pathways are well characterized and the metabolites easily predicted by looking for mass differences when comparing the parent drug with its metabolite. For example, glucuronide, sulfate, and glutathione metabolites are easily predicted by an increase in mass of 176, 80, and 305 Da, respectively, to the mass of the parent drug (Kostiainen et al., 2003;Levsen et al., 2005). Over the last decade, highly sensitive and specific analytical techniques such as LC/MS/MS, high resolution quadrupole-time-of-flight (Q-Tof) mass spectrometry, and LC/NMR have been widely applied to the study of drug metabolism. Not surprisingly, this has led to the recent discovery of a number of novel metabolites (Jaggi et al., 2002;Miao et al., 2005;Chang et al., 2006;Endo et al., 2007) and, in some cases, to the discovery of novel metabolic pathways (Tang et al., 2003;Yin et al., 2003;Zhen et al., 2006). Although many studies have been conducted on -lapachone (ARQ 501), there have been no previous reports on its metabolism either in animals or in humans. Preliminary metabolism studies for this compound were conducted with plasma from mice dosed intraperitoneally and rats dosed intravenously at 40 mg/kg with ARQ 501 formulated with HPCD. Later analyses were performed with human plasma samples obtained from a clinical study. In all species, the majority of conjugated product corresponds to glucuronidation or sulfation, but one metabolite representing a minor proportion of conjugate does not correspond to any commonly expected phase II metabolic process. The present study was conducted to characterize this rare metabolite, which has been identified as a novel glucosylsulfate conjugate. There are several accounts of a similar metabolic process occurring in cotton plants that were exposed to pesticides including profenofos (Capps et al.,...